Answers are grounded in this paper and cite their sources.
Introduction The development of new vaccines is often hampered by significant obstacles: vaccine heterogeneity, toxicity of additives (eg., immunostimulant), side effects (autoimmune and allergic responses), stability, and difficulties with characterization and manufacturing processes [1]. Most of these obstacles can be overcome by the design of a peptide subunit vaccine that contains
No takes yet. Share an insight, caveat, or question.
Skwarczyński et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: